Literature DB >> 19731000

Role of the disease in the psychological impact of pre-symptomatic testing for SCA2 and FAP ATTRV30M: Experience with the disease, kinship and gender of the transmitting parent.

Milena Paneque1, Carolina Lemos, Alda Sousa, Luis Velázquez, Manuela Fleming, Jorge Sequeiros.   

Abstract

To identify possible factors affecting the psychological impact of pre-symptomatic testing for spinocerebellar ataxia type 2 (SCA2) and familial amyloid polyneuropathy (FAP ATTRV30M), we studied (1) the effect of previous experience with the disease in the family, (2) kinship with the closest affected relative and (3) gender of affected parent, when adapting to test results; as well as (4) differences in the course of psychological wellbeing in 63 subjects ( 28 at-risk for FAP ATTRV30M, and 35 at risk for SCA2), who pursued predictive testing for these diseases, in Cuba and in Portugal. Our research shows that individuals with little or no experience with the disease in their family exhibited more anxiety; at-risk subjects for SCA2 or FAP ATTRV30M who had a first degree relative with the disease showed lower levels of anxiety and depression during pre-symptomatic testing. Also those with an affected mother had lower levels of depression, either immediately, or one year after receipt of test results. Adaptation to pre-symptomatic testing results differed for subjects at-risk for the two different conditions. Unlike the FAP ATTRV30M families, carriers for SCA2 reported pathological levels of depression immediately after-testing (3 weeks), although those levels had returned to normal levels at 6 months. Subjects at-risk for FAP ATTRV30M tended to have less anxiety than those tested for SCA2, at the one-year follow-up. Overall, depression levels improved over time, while anxiety remained more constant. A longer awareness of the disease in the family, closer kinship, and a transmitting mother all lessened the impact of pre-symptomatic testing, as expressed by the post-test levels of anxiety and depression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731000     DOI: 10.1007/s10897-009-9240-1

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  25 in total

Review 1.  Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I.

Authors:  L Rolim; A Leite; S Lêdo; M Paneque; J Sequeiros; M Fleming
Journal:  Clin Genet       Date:  2006-04       Impact factor: 4.438

2.  Presymptomatic testing for Huntington's disease in Wales 1987-90.

Authors:  A Tyler; M Morris; L Lazarou; L Meredith; J Myring; P Harper
Journal:  Br J Psychiatry       Date:  1992-10       Impact factor: 9.319

3.  Psychosocial aspects of familial breast and ovarian cancer: psychological guidelines for genetic testing.

Authors:  M Decruyenaere; G Evers-Kiebooms; E Claes; L Denayer; M Welkenhuysen; E Legius; K Demyttenaere
Journal:  Dis Markers       Date:  1999-10       Impact factor: 3.434

4.  Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study.

Authors:  Maria U Larsson; Mary A Luszcz; The-Hung Bui; Tarja-Brita Robins Wahlin
Journal:  J Genet Couns       Date:  2006-10       Impact factor: 2.537

5.  Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba.

Authors:  G Orozco Diaz; A Nodarse Fleites; R Cordovés Sagaz; G Auburger
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

6.  Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).

Authors:  G Holmgren; L Steen; J Ekstedt; C G Groth; B G Ericzon; S Eriksson; O Andersen; I Karlberg; G Nordén; M Nakazato
Journal:  Clin Genet       Date:  1991-09       Impact factor: 4.438

Review 7.  Predictive testing for Huntington disease: a psychologist's view.

Authors:  S Kessler
Journal:  Am J Med Genet       Date:  1994-09-15

8.  Internal consistencies of the original and revised Beck Depression Inventory.

Authors:  A T Beck; R A Steer
Journal:  J Clin Psychol       Date:  1984-11

9.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.

Authors:  Gustaf Herlenius; Henryk E Wilczek; Marie Larsson; Bo-Göran Ericzon
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

10.  "Holding your breath": interviews with young people who have undergone predictive genetic testing for Huntington disease.

Authors:  Rony E Duncan; Lynn Gillam; Julian Savulescu; Robert Williamson; John G Rogers; Martin B Delatycki
Journal:  Am J Med Genet A       Date:  2007-09-01       Impact factor: 2.802

View more
  11 in total

1.  Ethical dilemmas in genetic testing: examples from the Cuban program for predictive diagnosis of hereditary ataxias.

Authors:  Tania Cruz Mariño; Rubén Reynaldo Armiñán; Humberto Jorge Cedeño; José Miguel Laffita Mesa; Yanetza González Zaldivar; Raúl Aguilera Rodríguez; Miguel Velázquez Santos; Luis Enrique Almaguer Mederos; Milena Paneque Herrera; Luis Velázquez Pérez
Journal:  J Genet Couns       Date:  2011-01-25       Impact factor: 2.537

2.  Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing.

Authors:  Caroline Santa Maria Rodrigues; Viviane Ziebell de Oliveira; Gabriela Camargo; Claudio Maria da Silva Osório; Raphael Machado de Castilhos; Maria Luiza Saraiva-Pereira; Lavínia Schuler-Faccini; Laura Bannach Jardim
Journal:  J Genet Couns       Date:  2011-06-30       Impact factor: 2.537

3.  SCA2 predictive testing in Cuba: challenging concepts and protocol evolution.

Authors:  Tania Cruz-Mariño; Yaimeé Vázquez-Mojena; Luis Velázquez-Pérez; Yanetza González-Zaldívar; Raúl Aguilera-Rodríguez; Miguel Velázquez-Santos; Annelié Estupiñán-Rodríguez; José Miguel Laffita-Mesa; Luis E Almaguer-Mederos; Milena Paneque
Journal:  J Community Genet       Date:  2015-04-19

Review 4.  A comprehensive review of spinocerebellar ataxia type 2 in Cuba.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Julio Cesar García-Rodríguez; Luis Enrique Almaguer-Mederos; Tania Cruz-Mariño; José Miguel Laffita-Mesa
Journal:  Cerebellum       Date:  2011-06       Impact factor: 3.847

5.  Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.

Authors:  Alice Lopes; Alexandra Sousa; Isabel Fonseca; Margarida Branco; Carla Rodrigues; Teresa Coelho; Jorge Sequeiros; Paula Freitas
Journal:  J Community Genet       Date:  2017-10-19

Review 6.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

7.  Ethical, social, and cultural issues related to clinical genetic testing and counseling in low- and middle-income countries: a systematic review.

Authors:  Adrina Zhong; Benedict Darren; Bethina Loiseau; Li Qun Betty He; Trillium Chang; Jessica Hill; Helen Dimaras
Journal:  Genet Med       Date:  2018-08-03       Impact factor: 8.822

8.  Genetic counseling and presymptomatic testing programs for Machado-Joseph Disease: lessons from Brazil and Portugal.

Authors:  Lavínia Schuler-Faccini; Claudio Maria Osorio; Flavia Romariz; Milena Paneque; Jorge Sequeiros; Laura Bannach Jardim
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

9.  Psychopathological Dimensions in Portuguese Subjects with Transthyretin Familial Amyloid Polyneuropathy.

Authors:  Alice Lopes; Isabel Fonseca; Alexandra Sousa; Margarida Branco; Carla Rodrigues; Teresa Coelho; Jorge Sequeiros; Paula Freitas
Journal:  Biomed Hub       Date:  2017-12-13

Review 10.  Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.

Authors:  Laura Obici; Jan B Kuks; Juan Buades; David Adams; Ole B Suhr; Teresa Coelho; Theodore Kyriakides
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.